(3S)-3-[(2S)-3-[(1R)-1-[(4S,6S)-4-[(1R,2E,4E)-6-(4-chloro-3-methoxyphenyl)-1-methoxy-5-methylhexa-2,4-dienyl]-4-hydroxy-2-oxo-1,3-oxazinan-6-yl]ethyl]-2-methyloxiran-2-yl]-3-hydroxy-N-methylpropanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3S)-3-[(2S)-3-[(1R)-1-[(4S,6S)-4-[(1R,2E,4E)-6-(4-chloro-3-methoxyphenyl)-1-methoxy-5-methylhexa-2,4-dienyl]-4-hydroxy-2-oxo-1,3-oxazinan-6-yl]ethyl]-2-methyloxiran-2-yl]-3-hydroxy-N-methylpropanamide
• 化学式: C₂₈H₃₉ClN₂O₈
• 分子量: 567.1
• InChiKey: KGSYOWIKEIFGGO-BNLAWCHYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  39
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  139
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• [EN] PREPARATION OF MAYTANSINOID ESTERS<br/>[FR] PRÉPARATION D'ESTERS DE MAYTANSINOÏDE
  申请人：BIO THERA SOLUTIONS LTD

  公开号：WO2014094354A1

  公开（公告）日：2014-06-26

  Provided are efficient methods for direct coupling of a maytansinoid with a carboxylic acid to prepare a maytansinoid C-3 ester in high yield using a rare earth metal-based or trifluoromethanesulfonate-based Lewis acid catalyst and a base together with a coupling reagent. Also provided are compositions used in such methods.

  提供了一种高效的方法，用稀土金属基或三氟甲磺酸盐基的路易斯酸催化剂和碱以及偶联试剂直接偶联马坦西酮与羧酸，以高收率制备马坦西酮C-3酯。还提供了在这种方法中使用的组合物。
• [EN] COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES<br/>[FR] COMPOSÉS ET PROCÉDÉS PERMETTANT LE TRAITEMENT DE PATHOLOGIES ERB B2/NEU POSITIVES
  申请人：BIO THERA SOLUTIONS LTD

  公开号：WO2014094527A1

  公开（公告）日：2014-06-26

  Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.

  本文披露了与马替南素类药物结合的抗ERB B2/NEU抗体，用于靶向传递至疾病组织。提供了关于准备和使用这种药物结合物来治疗癌症中的ERB B2/NEU阳性细胞的方法。
• [EN] COMPOUNDS AND METHODS FOR THE TREATMENT OF CD20 POSITIVE DISEASES<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DES MALADIES CD20 POSITIVES
  申请人：BIO THERA SOLUTIONS LTD

  公开号：WO2014094528A1

  公开（公告）日：2014-06-26

  Disclosed herein are anti-CD20 antibody conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat CD20 positive cells in cancers are provided.